Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma

1 Mar 2025

Abstract excerpt

Purpose: Mepolizumab, which causes a decrease in the number of blood eosinophils, is used to treat patients with severe eosinophilic asthma (SEA). However, there is a relative lack of data on dynamic changes in blood eosinophil subtype distribution and their granule protein expression following anti-interleukin (IL)-5 treatment. Our objective was to evaluate blood inflammatory-like (iEOS-like) and resident-like...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Eosinophilic Disorders and Syndromes
Share to Eosinophilic Esophagitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40177298
DOI: 10.2147/jaa.s509001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic AsthmaPMID 40177298Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.Semantic proximity Read ↗

Lessons learned from targeting eosinophils in human disease.Semantic proximity Read ↗

Eosinophils: Biological Properties and Role in Health and DiseaseSemantic proximity Read ↗

Reslizumab in the treatment of severe eosinophilic asthma: an update.Semantic proximity Read ↗

Single cell RNA-seq discovery of blood biomarkers predicting treatment outcome in severe asthma patientsSemantic proximity Read ↗

Monitoring eosinophils to guide therapy with Biologics in Asthma: does the compartment matter?Semantic proximity Read ↗

Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Reslizumab and Eosinophilic Asthma: One Step Closer to Phenotype-directed Therapy?Semantic proximity Read ↗

Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment.Semantic proximity Read ↗

Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.